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Abstract
Background: In patients with major depressive disorder (MDD), antidepressant response and remission rates are low,
highlighting the need for new treatment approaches. Recently, the abundant literature linking inflammatory processes
and depressive symptoms have led to the hypothesis that selecting treatment for MDD based on the patient’s
inflammatory status could be a promising strategy to improve outcomes in patients suffering from MDD. The aim of
the randomised control trial we propose is to investigate the antidepressant efficacy of the combined treatment of
MDD with antidepressant medication plus anti-inflammatory medication in individuals with raised inflammation levels.
For the first time, this study will prospectively test the efficacy of an antidepressant plus anti-inflammatory
augmentation based on baseline inflammatory maker levels in MDD using a randomised controlled trial design.
Methods: This study proposes to measure blood C-reactive protein (CRP) levels before the initiation of treatment in
200 participants with MDD. Study participants are then assigned into one of two study strata: either into the
‘Depression with inflammation’ stratum (CRP levels > 3 mg/L); or into the ‘Depression without inflammation’ stratum
(CRP levels ≤ 3 mg/L). Within each of the two study strata, participants randomly receive either antidepressant
medication alone (vortioxetine) plus anti-inflammatory medication (celecoxib) or vortioxetine plus placebo for
six weeks. At the end of the treatment period, participants have the opportunity to continue vortioxetine alone for a
six-month post-trial period. Clinical outcomes are measured at baseline, fortnightly during the treatment period and at
the three-month and six-month post-trial visits. The primary outcome is change in MADRS score, with a primary
endpoint of a score reduction by 50% from baseline to six weeks (end of augmentation treatment with celecoxib).
Secondary clinical outcomes are changes in the cognitive dimensions of depression (cognitive function, emotion
processing and social cognition). Biological outcome measures (levels of CRP and other inflammatory markers) are
measured at baseline, after six weeks of treatment and at the six-month post-trial visit.
Discussion: The current study will generate novel evidence for biomarker-based personalised antidepressant treatment
selection based on patient inflammatory status before treatment.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12617000527369p. Registered on 11
April 2017.
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Background
It is estimated that antidepressant medications may have
therapeutic efficacy in as few as one-third of patients
with major depressive disorder (MDD) [1, 2]. Further-
more, antidepressant treatment is currently selected on
the basis of clinical symptoms only, including reported
symptoms and observable mental state changes, making
it difficult for the clinician to select the right treatment.
Several studies have highlighted a role of inflamma-
tory processes in the development of depressive symp-
toms in a subgroup of patients with MDD. The central
nervous system (CNS) has long been considered an
immune-privileged organ, but abundant evidence docu-
ments bi-directional communication with the periph-
eral immune system [3]. Inflammatory cytokines
released peripherally by immune cells can reach the
brain through humoral, nervous and chemical pathways
and hence act within the CNS [4, 5]. In the brain, in-
flammatory cytokines lead to the activation of glial cells
(i.e. microglia and astrocytes) and coordinate a set of
behavioural changes referred to as sickness behaviour
in sick individuals [6–8]. Cytokines are strong modula-
tors of several biological systems involved in behav-
ioural regulation, such as mood regulation [6, 9].
In the context of chronic inflammation, sustained brain
immune cell activation and cytokine production can lead
to the development of neuropsychiatric symptoms. In-
deed, pro-inflammatory mediators can induce depressive
symptoms, with up to 80% of interferon-α (IFN-α) treated
patients suffering from mild to moderate depressive symp-
toms [10–14]. Interestingly, these symptoms can be pre-
vented or treated with antidepressants [11, 15, 16].
Numerous studies have consistently associated inflamma-
tion and somatic diseases comprising inflammatory pro-
cesses, such as infections and autoimmune diseases, with
an increased risk of depression [17–22]. In addition,
studies have consistently shown increased levels of
pro-inflammatory markers among individuals with de-
pression, particularly during acute phases [23–25].
Meta-analyses have gathered large evidence, particu-
larly with C-reactive protein (CRP) [25, 26],
interleukin-6 (IL-6) [23–27], tumour necrosis factor-α
(TNF- α) [23, 24, 27] and IL-1 receptor antagonist
(IL-1ra) [24–26] being elevated among patients with
depression. Interestingly, levels of IL-6 decreased after
treatment of the acute depressive episode [24]. Also of
note is a recent brain imaging study, which found in-
creased microglial activation, indicating neuroinflam-
mation, among 20 individuals suffering an active
depressive episode compared to 20 healthy matched
controls [28].
Since depression is a very heterogeneous disorder, it is
noteworthy that recent studies have suggested that in-
flammatory components may be used to characterise a
specific subgroup of patients with depression. Baseline
increased levels of pro-inflammatory markers such as
CRP have been linked to greater depressive symptom se-
verity in general [25, 29–33] and also to greater severity
of symptoms, such as mood symptoms, interest, activity,
suicidality and cognitive symptoms of MDD [30]. In
addition, in a retrospective analysis of a clinical trial
using the TNF-α blocker infliximab to treat depressive
symptoms, it was suggested that moderately increased
levels of CRP at baseline might be indicative of response
to infliximab; however, the study was preliminary with a
small sample size of 60 patients and the conclusion was
based on 13 patients showing response and 11 patients
showing no response to infliximab [34]. However, the
proof of concept that CRP levels at baseline might be in-
dicative of treatment response to anti-inflammatory
treatments in depression has not been studied prospect-
ively yet. This approach may help to identify those indi-
viduals who may benefit from a targeted treatment
approach, potentially leading to more tailored and more
effective treatment in groups of MDD patients. More-
over, a recent systematic review and meta-analysis of
clinical trials recommended that the field now needs
randomised controlled trials (RCTs), using depression as
the primary outcome, in individuals with high inflamma-
tion levels [35]. This review also noted that targeting in-
flammatory markers would be a move towards novel,
effective and personalised treatment of depression.
Recent work from our group has addressed the issue of
selecting treatment for MDD based on inflammation sta-
tus. Two of these publications found emerging evidence
that anti-inflammatory evidence may need to be tailored
based on the patient’s inflammatory profile [36, 37]. In
other recent work from our group, a systematic review
of the efficacy of non-steroidal anti-inflammatory drugs
(NSAIDs) in depression concluded that translation of
using effective anti-inflammatory treatment has failed so
far and that further work, such as the clinical trial we
propose, is urgently needed to translate this potentially
significant treatment to clinical practice and improve pa-
tients’ mental health outcomes in depression [38].
We therefore propose that testing CRP levels in a
blood test before the commencement of treatment in pa-
tients with MDD will give clinicians an informative bio-
marker at hand to guide the selection of effective
antidepressant treatment. CRP was chosen as the in-
formative inflammatory marker not only because it can
predict improvement in depressive symptoms following
anti-inflammatory treatment [34] but also because CRP
detection in the blood can be routinely done in path-
ology services and hence shows potentially high clinical
utility. Vortioxetine was chosen as the antidepressant
medication; since it has a recently obtained Therapeutic
Goods Administration (TGA) indication in Australia for
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the treatment of MDD, it is more likely to be useful in
severe depression [39] and is likely to be useful in en-
hancing the remittance of cognitive symptoms of depres-
sion [40]. It will be novel to investigate its potential
immune-modulatory effects in secondary analyses. Cele-
coxib was chosen as the trial anti-inflammatory medica-
tion because of its ability to increase the efficacy of
antidepressant medication when used as an augmenta-
tion strategy [41, 42]. This is a first adequately powered,
RCT that prospectively tests the efficacy of an anti-
depressant plus adjunctive anti-inflammatory treatment
based on baseline CRP levels in MDD. This approach
will inform real-world treatment of depression based on
a widely available blood test.
Methods and design
Objectives
The primary objective of this study is to investigate the
antidepressant efficacy, measured by Montgomery–
Åsberg Depression Rating Scale (MADRS) score, of the
six-week combined treatment of MDD with antidepres-
sant medication (vortioxetine) plus anti-inflammatory
medication (celecoxib). We hypothesise that a higher ef-
ficacy and larger reduction in symptoms of depression
will be observed after six weeks when treatment is com-
bined (antidepressant and anti-inflammatory) compared
to the treatment with antidepressant alone, in individ-
uals with baseline inflammation (i.e. with baseline CRP
levels > 3 mg/L). In addition, we hypothesise that no dif-
ference between treatments will be observed in individ-
uals with no baseline inflammation (i.e. with baseline
CRP levels < 3 mg/L) (see Table 1).
The secondary objectives of the study are:
1. To investigate the anti-inflammatory effects of a com-
bined treatment of MDD with vortioxetine and cele-
coxib in individuals with baseline inflammation (CRP
levels > 3 mg/L) over a six-week period. We aim to
demonstrate a larger reduction of circulating levels of
the inflammatory marker CRP in the group of de-
pressed patients who are treated with antidepressant
plus anti-inflammatory medication (see Table 1).
2. To test whether there is evidence of a different
effect of the combined treatment in the two
inflammation strata, although the study is not
powered to detect this effect (see Table 1).
3. To investigate the safety of the anti-inflammatory
treatment of celecoxib 400 mg when combined with
vortioxetine (see Table 1).
4. To investigate the effects of vortioxetine on
cognition (using the THINC-It tool) and on psycho-
social and workplace performance measures in
MDD (see Table 1).
Recruitment and study design
A total of 200 patients with MDD will be included in the
study. Recruitment and treatment take place in the wider
Central Adelaide Local Health Network (CALHN), with
all participant appointments being held in the Clinical
Research Facility in the Health and Medical Sciences
Building, Discipline of Psychiatry, University of Adelaide.
In addition to this, and to ensure that required numbers
of study participants are recruited, people from the
general population who meet the inclusion criteria are
Table 1 Objectives and hypotheses of the study. Table stating study objectives and hypothesis in a generic way and in a
drug-specific way
Generic way Drug-specific way
Primary
objective
To investigate the antidepressant efficacy of the 6-week combined
treatment of MDD with antidepressant plus anti-inflammatory
To investigate the antidepressant efficacy of the 6-week combined
treatment of MDD with vortioxetine plus celecoxib 400 mg
Primary
hypothesis
A higher efficacy and larger reduction in symptoms of depression
will be observed after 6 weeks when treatment is combined
(antidepressant and anti-inflammatory) in individuals with
baseline inflammation
A higher efficacy and larger reduction in symptoms of depression
will be observed after 6 weeks when treatment is combined




To investigate the anti-inflammatory effects of a combined
treatment of MDD with antidepressant and anti-inflammatory
in individuals with baseline inflammation (CRP levels > 3 mg/L)
over a 6-week period
To investigate the anti-inflammatory effects of a combined
treatment of MDD with vortioxetine and celecoxib 400 mg in




A larger reduction of circulating levels of the inflammatory marker
CRP will be observed in the group of depressed patients who are
treated with antidepressant plus anti-inflammatory medication
A larger reduction of circulating levels of the inflammatory marker
CRP will be observed in the group of depressed patients who are
treated with vortioxetine plus celecoxib 400 mg
Secondary
objective 2
To test whether there is evidence of a different effect of
the combined treatment in the two inflammation strata
To test whether there is evidence of a different effect of the
combined treatment with vortioxetine and celecoxib 400 mg in
the two inflammation strata
Secondary
objective 3
To investigate the safety of the anti-inflammatory treatment
when combined with antidepressant




To investigate the effects of the antidepressant on cognition,
psychosocial and workplace performance measures in MDD
To investigate the effects of vortioxetine on cognition,
psychosocial and workplace performance measures in MDD
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able to engage with the proposed study, as it is made avail-
able through advertisement. Participants are free to with-
draw from the study at any time.
The study is designed as a parallel group RCT with a
superiority framework, investigating 200 participants
with MDD over six weeks in the primary phase followed
by a six-month post-RCT follow-up period (Fig. 1). The
study proposes to measure the inflammatory marker
CRP before the commencement of treatment. Following
CRP measurement, study participants are then assigned
into one of two study strata based on CRP levels. The
first of these study strata is made up of 100 individuals
with CRP levels > 3 mg/L (the ‘Depression with inflam-
mation’ stratum) and the second study stratum is an ac-
tive control, made up of 100 individuals with CRP levels
≤ 3 mg/L (the ‘Depression without inflammation’
stratum). In each stratum, participants are randomly al-
located in a 1:1 ratio to augmentation of vortioxetine
antidepressant treatment with either celecoxib or pla-
cebo. Following six weeks of concomitant administration
of celecoxib or placebo with vortioxetine, the celecoxib
or placebo is then stopped and the participants are
treated with vortioxetine only for an additional two
weeks. This allows the opportunity to assess the efficacy
of taking vortioxetine alone. While the primary time
point is the six weeks in which we compare vortioxetine
with augmentation against vortioxetine without augmen-
tation, following the RCT phase, all participants have
the opportunity to continue on vortioxetine without cel-
ecoxib or placebo for another six months during a
post-RCT observational study period.
The principal investigator (PI) and trial psychiatrist are
aware which study participants are receiving celecoxib
and which participants are receiving placebo, so that the
dose of vortioxetine can be determined. An approxi-
mately twofold increase in vortioxetine plasma concen-
tration has been observed following co-administration of
bupropion, a strong CYP2D6 inhibitor [43]. When bu-
propion was added to vortioxetine 10 mg daily at steady
state, a higher incidence of adverse events was observed
than when vortioxetine was added to bupropion at
steady state. This may be explained by pharmacodynam-
ics or combined pharmacodynamic/pharmacokinetic ef-
fects following CYP2D6 inhibition with bupropion,
which seem to be more pronounced when the inhibition
is initiated when vortioxetine is in steady state than before
vortioxetine is administered [43]. In the study where bu-
propion was added to vortioxetine, increased incidences
of nausea, headache and vomiting were noted [43]. As cel-
ecoxib is also a strong inhibitor of CYP2D6, individuals
receiving celecoxib start at a lower dose of vortioxetine,
5 mg daily, and are restricted to a maximum dose of
10 mg daily for the duration of co-administration. This is
consistent with guidelines recommending the dose of vor-
tioxetine be reduced by half if a strong CYP2D6 inhibitor
is co-administered (Trintellix Product Monograph. Page 1
of 44, Lundbeck).
Furthermore, dosage of vortioxetine will vary to a
small extent between participants even in the same
strata, treatment group and time point. This is due to
differences in CYP2D6 metabolic functionality in the
general population related to common genetic variants
[44]. Unfortunately, testing for genetic markers of
CYP2D6 dysfunction at baseline, or plasma concentra-
tion of vortioxetine in all participants at all necessary
time points, is beyond the scope of this study. Neverthe-
less, we account for this in two ways. First, for the safety
and comfort of participants, each person will be started
Fig. 1 Clinical timeline of the trial. Participants will complete assessment sessions fortnightly over the 8-week RCT period. “R” circles represent 1:1
random assignment of participants within each study stratum
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on a low dose and only increase if and when acceptable
tolerability is demonstrated, as measured by a low num-
ber and mild severity of side effects reported to trial re-
searchers on an in-house side effects questionnaire. The
possible doses by strata and treatment group are given
in Fig. 2. We are also able to assume, using this method,
that the plasma concentration is comparable between all
participants throughout the trial [44]. Additionally, the
variable of dose differences will be factored into statis-
tical analysis by noting the cumulative total dose of vor-
tioxetine per participant over the entire study.
To promote participant retention, study participants
are encouraged to contact the study team if any side ef-
fects cause them serious concern between appointments,
allowing for the dosage of vortioxetine to be lowered if
possible, in the hope of reducing the likelihood of early
withdrawal from the study. In the case of early with-
drawal from the study, all endpoint scales and blood col-
lection will be conducted immediately for later analysis.
Double-blinding
The trial psychiatrist and the study PI do not administer
the MADRS or any of the functional rating scales, as
they are aware of both the dose of vortioxetine and
whether a participant is receiving celecoxib or placebo.
While the PI is aware which study participants are re-
ceiving celecoxib and which participants are receiving
placebo, the study rater and participants remain fully
blinded during the entire trial. Celecoxib has been encap-
sulated to have the same appearance as placebo; celecoxib
and placebo have been packaged in the same way. A ran-
domisation list has been created by the Royal Adelaide
Hospital pharmacy and provided to the trial psychiatrist.
The dosage of vortioxetine is not marked specifically on
the package provided to participants in order to maintain
blinding of participants as well as researchers administer-
ing the scales who may see the boxes.
Study sample size
Given a power of 0.95, and an alpha error of 0.05, the
study sample size required to detect a change in
MADRS of an effect size of 0.25 between baseline and
week 6 would be 50 study participants in each of the
four groups. This would be a total of 200 study partici-
pants (100 participants in the ‘Depression with inflam-
mation’ stratum and 100 study participants in the
‘Depression without inflammation’ stratum; 50 partici-
pants in each treatment group, respectively).
We have found in our internal analyses that around
40–50% of individuals have a CRP level of > 3 mg/L,
so we expect to be able to recruit 100 participants to
the ‘Depression with inflammation’ stratum and 100
participants to the ‘Depression without inflammation’
stratum. The proposed study duration is two years,
which will allow time to recruit the required number
of study participants.
Fig. 2 Diagram stating the possible dosages of vortioxetine (antidepressant medication) and celecoxib (anti-inflammatory medication) within
each group for all the periods of the trial
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Study schedule
During the screening visit, detailed study information is
provided to participants (see Additional file 1) and written
informed consent obtained (see Additional file 2). A mem-
ber of the research team assesses symptoms severity and
participant’s eligibility and measures vital signs. Following
a blood test, participants are allocated into the ‘Depression
with inflammation’ or ‘Depression without inflammation’
strata of the study. Study participants are taken off their
regular antidepressant medication after screening and in
the week before trial medication is started.
During the baseline visit, demographics (including
date of birth, sex and race) and years of education are
recorded. In addition, psychiatric and medical history,
number of psychotropic medications received, alcohol
and nicotine history, vital signs and anthropometric data
are collected. A physical examination is also performed
during this visit.
According to stratified recruitment into the two treat-
ment strata and the random allocation into two treat-
ment groups, participants in both the ‘Depression with
inflammation’ and ‘Depression without inflammation’
stratum receive celecoxib 400 mg daily or placebo. The
starting dose of vortioxetine in both study strata is vor-
tioxetine 5 mg daily for those receiving celecoxib, due to
possible drug–drug interactions, and vortioxetine 10 mg
daily for those receiving placebo. Two weeks after com-
mencement of treatment, participants receiving vortiox-
etine 5 mg daily and 10 mg daily are provided the
opportunity to increase to vortioxetine 10 mg or 20 mg
daily, respectively, following an assessment by a research
clinician (Fig. 2). The decision to increase the dose or to
leave it the same is made by the trial psychiatrist after
review of the change in depressive symptoms from base-
line according to the MADRS and the presence and se-
verity of side effects, rated by a blinded researcher. The
dose of vortioxetine is increased only if the side effects
experienced are easily manageable and the participants
have not achieved recovery (MADRS score < 7). In study
participants reporting symptoms consistent with an ex-
cessive plasma concentration of vortioxetine, the trial
psychiatrist will reduce the dose of vortioxetine without
informing the participant or blinded researchers admin-
istering scales. After six weeks of treatment, celecoxib
and placebo are ceased, but the antidepressant vortioxe-
tine is continued for at least two weeks. After the com-
pletion of the RCT phase, study participants are given
the opportunity to continue taking vortioxetine into the
post-RCT study phase for up to six months. Following
an assessment by a research clinician, study participants
who had been taking vortioxetine 5 mg or 10 mg daily
during the RCT due to celecoxib co-administration are
given the opportunity to increase to vortioxetine 10 mg
and 20 mg daily, respectively; otherwise vortioxetine is
continued in the post-RCT phase at the same dose as
for the RCT phase.
A member of the research team assesses symptoms se-
verity, cognitive function, functional and workplace prod-
uctivity, and other secondary assessments at baseline visit,
fortnightly during the RCT period, and at the three-month
and six-month post-RCT visits (see Fig. 1). Participants are
asked to report any treatment side effects at each visit.
They are also asked to return the vortioxetine packages at
each fortnightly visit and receive new ones regardless of
whether they have finished a packet or not, so that compli-
ance can be gauged. Similarly, the celecoxib or placebo
medication is also returned at the end of six weeks.
An additional checklist and an additional figure have
been provided for further details regarding the study of
enrolment, interventions and assessments for the
current study (Additional file 3 and Fig. 3).
Inclusion and exclusion criteria
Participants with MDD are selected according to the fol-
lowing selection criteria: they must be aged 18–75 years;
be outpatients in a psychiatric setting with MADRS
score ≥ 26 at screening and baseline visits; have at least
one prior episode of depression, validated by previous
treatment; and the current major depressive episode
(MDE) is confirmed by the MINI and has a duration of at
least three months. Exclusion criteria are: current alcohol
and/or substance use disorder; presence of a co-morbid
psychiatric disorder as a focus of clinical concern; primary
inflammatory or immune-related disorder; neurodegenera-
tive disorder; history of neurological disorder; past peptic
ulcer disease or history of gastrointestinal (GI) bleeding;
unstable coronary artery or cardiovascular disease; renal
impairment; physical, cognitive, reading, and learning or
language impairment. In addition, past hypersensitivity to
vortioxetine or to celecoxib and use of concomitant medi-
cations able to affect cognitive function or to induce drug–
drug interaction are also considered exclusion criteria.
Data storage and participant confidentiality
Data are stored both on secure, password-protected in-
ternal servers and also physically in locked storage
space in locked rooms, accessible only to researchers
on the trial individually approved by the Ethics Com-
mittee mentioned below. Biological specimens are
marked with a code unidentifiable to persons unaffili-
ated with the project. Prepared data reports may be
shared with future collaborators but do not contain
identifiable participant information. Data will be stored
for 15 years after study completion. The results of the
trial will be made publicly available via official publica-
tion and media release at the trial’s conclusion.
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An independent Data Monitoring Committee (DMC)
will be formed and comprise experienced local, national
and international members.
Ethics
The study was approved by the Royal Adelaide Hospital
Human Research Ethics Committee (HREC; reference
number R20170320 HREC/17/RAH/111). Study partici-
pants have all study details explained to them in writing
and in person by a member of the study team before giv-
ing written informed consent. The consent form states
that refusal to participate or subsequent withdrawal
from the study will in no way influence any treatment
that the participant would receive, at the time of the
study or in the future. Any and all serious adverse events
to occur considered to be related to the trial are re-
ported to the aforementioned HREC by the PI. In the
event of participants suffering harm due to the study,
the trial is covered by indemnity insurance.
Medications
Celecoxib
Celecoxib, a cyclooxygenase 2 inhibitor, is a NSAID that
has previously been used as an adjunct to antidepressant
medication in the treatment of MDD in four trials, with
three of these trials exploring six weeks of treatment at
400 mg daily [45–47] and one trial of eight weeks at
200 mg daily [48]. All four of these trials suggested im-
proved antidepressant treatment effects for celecoxib
add-on treatment, compared to antidepressants plus pla-
cebo. Recent meta-analyses associated celecoxib with
an increased efficacy of antidepressant therapy [41]. In
particular, augmentation of antidepressant medication
with celecoxib showed an improved antidepressant effect
by a standard mean difference (SMD) of 0.82 (95% confi-
dence interval [CI]: 0.46–1.17) and without heterogeneity
between the studies (I2 = 0%) [41]. Furthermore, remission
of depression was improved by an odds ratio (OR) of 7.89
(95% CI: 2.94–21.17) and treatment response by an OR of
Fig. 3 SPIRIT figure. Schedule of enrolment, interventions and assessments
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6.59 (95% CI: 2.24–19.42) by this 6–8-week add-on treat-
ment hence the choice of celecoxib 400 mg for our study.
Finally, one trial included peripheral blood tests and found
that higher levels of the pro-inflammatory marker IL-6
predicted better antidepressant response to the celecoxib
add-on [45]. In the present study, celecoxib 400 mg or
placebo is given daily to all the participants at a constant
dosage from baseline to week 6.
Vortioxetine
Vortioxetine has been chosen as it has a TGA indication in
Australia for the treatment of MDD. The Royal Australian
and New Zealand College of Psychiatrists (RANZCP)
guidelines for the treatment of MDD include use of anti-
depressant medication such as vortioxetine. The RANZCP
guidelines state vortioxetine is most likely to be useful in
melancholia and severe depression [39]. Furthermore, vor-
tioxetine is the only antidepressant listed in the RANZCP
guidelines that is likely to be useful in enhancing the remit-
tance of cognitive symptoms of depression [39], since it
has been demonstrated to have beneficial effects on the
cognitive symptoms seen in MDD [40].
All the study medication will be provided for free over
the entire RCT and post-RCT periods, for eight months
in total.
Clinical, self-report and cognitive assessment
When not self-administered, the following clinical and
cognitive assessment are administered by a clinician re-
searcher who is blind to whether participants receive
celecoxib or placebo. The administering researcher has
been trained in all clinician-rated scales. These scales
have been referred to as ‘clinician-administered ques-
tionnaire’ in the text. A summary of all scales used in
the study can be found in Table 2 (see Table 2). The
table lists whether the rater is a study clinician who is
blinded to anti-inflammatory or placebo medication sta-
tus and baseline CRP level, or self-administered. While
many scales are self-administered, they are all completed
under the supervision of research personnel who can
offer clarification if required.
Diagnostic interview and symptom severity
Montgomery–Åsberg Depression Rating Scale (MADRS)
Study participants are evaluated with the MADRS at the
screening and baseline visits to assure the score is ≥ 26,
according to inclusion criteria and at RCT and
post-RCT visits. The MADRS is a frequently used and
well-validated clinician-administered questionnaire con-
sisting of 10 items assessing the following depressive
symptoms: apparent sadness; reported sadness; inner
tension; reduced sleep; reduced appetite; concentration
difficulties; lassitude; inability to feel; pessimistic
thoughts; and suicidal thoughts. All of the items are
rated from 0 to 6. The clinician must decide whether the
rating lies on the defined scale steps (0, 2, 4, 6) or between
them (1, 3, 5). This clinician-rated scale allows assessment
of the severity of depressive symptoms. The total score is
in the range of 0–60 and the higher the global score, the
more serious the depressive symptoms. It is designed to
be sensitive to change resulting from antidepressant ther-
apy [49]. Internal rater consistency is controlled by having
all trained clinician researchers complete rating scales
based on standard video interviews.
Mini-International Neuropsychiatric Interview (MINI)
The diagnosis of MDD is confirmed using the MINI dur-
ing the screening visit. The MINI is a widely used struc-
tured diagnostic interview which enables clinicians to
make diagnoses of psychiatric disorder [50, 51]. It is a
clinician-administered questionnaire divided into modules
corresponding to diagnostic categories (MDD, suicidality,
bipolar disorder, panic disorder, agoraphobia, social pho-
bia, obsessive-compulsive disorder, post-traumatic stress
disorder, alcohol dependence/abuse, substance depend-
ence/abuse, psychotic disorder and mood disorder with
psychotic features, anorexia nervosa, bulimia nervosa, gen-
eralised anxiety disorder, antisocial personality disorder).
The diagnosis of MDD is confirmed if participants experi-
ence five or more of nine symptoms (depressed mood, loss
of interest, significant weight loss or gain or decrease or
increase in appetite, insomnia or hypersomnia, psycho-
motor agitation or retardation, fatigue or loss or energy,
feelings of worthlessness or excessive or inappropriate
guilt, diminished ability to think or concentrate or indeci-
siveness, recurrent thoughts of death or recurrent suicidal
ideation without a specific plan or suicide attempt or a
specific plan) including depressed mood or loss of interest.
Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a widely used clinician-administered ques-
tionnaire for assessment of suicidal ideation or behaviour
of participants [52]. It consists of a series of questions
assessing suicide ideation, action taken to prepare for sui-
cide and whether participants attempted suicide or began
a suicide attempt.
Functioning
National Adult Reading Test (NART)
The NART is used to estimate premorbid intelligence
[53]. It consists of a list of 50 irregularly pronounced
words in order of increasing difficulty. The participants
have to read aloud down this list of words and the num-
ber of pronunciation errors is recorded. The clinician
has previously been familiarised with all the words be-
fore administering the test.
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Clinical Global Impression scale (CGI)
The CGI scale is an easy tool to quantify patient pro-
gress and treatment response over time. It assesses the
clinician’s view of patient global functioning at baseline
and after initiation of treatment. The CGI has two com-
ponents: the CGI-Severity, which rates illness severity,
and the CGI-Improvement, which rates change from
baseline [54].
Functioning Assessment Short Test (FAST)
The FAST is a clinician-administered questionnaire re-
ferring to the last 15 days before assessment. It consists
Table 2 Table summarising all clinician-administered and self-administered scales used in the study. Study scales used in the
anti-inflammatory treatment of depression study, their range, cutoff for study eligibility and rater identity




Detect the presence and severity
of depressive symptoms
0–60 (0–6 = normal/recovered;
7–19 = mild depression;
20–34 =moderate depression;
and 35–60 = severe depression)









Fulfilment or non-fulfilment of minimum
diagnostic criteria for Axis I neuropsychiatric









Relative severity of suicidal ideation and
behaviour in the last month and lifetime
0–33, where the higher the number,
the greater the severity of ideation and






Predictor of IQ, independent of
psychiatric morbidity







Allows for quantification of patient
morbidity (CGI-S), and progress and
treatment response over time (CGI-I)
2 scales of 0–7; in CGI-S, 0 is normal while
7 indicates complete disability; and in CGI-I,
0 indicates substantial improvement while






The extent of difficulty the participant
has had in specific areas of everyday
life in the specified timeframe
0–72, where the higher the number,






Estimates the participant’s well-being by
gauging the proportion of time spent in a
positive state of mind in the last 2 weeks
0–100, where the higher the number,





Assessment of productivity when at
work and record of hours worked
0–100, where the higher the number,





Assessment of impairment to full
functional capacity at work
0–100, where the higher the number, the less






The degree to which the participant
has been impaired in work/school,
social and family life due to disability
3 scales from 0 to 10, considered independently







Participant’s own recollection of
cognitive difficulties in the past 7 days
0–20, where the higher the number, the greater
the perceived cognitive deficit; score can also be
multiplied by 200 to give the same scoring range
as the subsequent THINCit® tests
N/A Self-administered
THINC-it® Spotter Test of attention and response speed Overall score: 0–4000, where a higher number
indicates greater ability in all measures;
additionally, accuracy (range: 0–40) and speed




Test of working memory and attention Overall score: 0–4000, where a higher number
indicates greater ability in all measures; additionally,
accuracy (count correct vs incorrect) and speed




Test of attention, perceptual speed,
motor speed, visual scanning and
memory
Overall score: 0–4000, where a higher number
indicates greater ability in all measures; additionally,
accuracy (count correct vs incorrect) and speed
(mean response time, maximum 1 s) are recorded
N/A Self-administered
THINC-it® Trails Test of visual search speed, scanning,
speed of processing, mental flexibility
and executive functioning
Overall score: 0–4000, where a higher number
indicates greater ability in all measures; additionally,
accuracy (count correct vs incorrect, error type) and
speed (total completion time) are recorded
N/A Self-administered
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of 24 items divided among the following six areas of
functioning: autonomy; occupational functioning; cogni-
tive functioning; financial issues; interpersonal relation-
ships; and leisure time. All of the items are rated from 0
(no difficulty) to 3 (severe difficulty); the higher the glo-
bal score, the more serious the difficulties [55].
WHO-5 Well-Being Index
The WHO-5 Well-Being Index is a short, self-administered
questionnaire that measures current mental well-being of
participants. It consists of five items related to mood, vitality
and general interests. It is a reliable measure of emotional
functioning and a good screening tool for depression [56].
Work productivity
Endicott Work Productivity Scale (EWPS)
The EWPS is a self-administered questionnaire assessing
work productivity. It consists of 25 items and measures
presenteeism and the frequency of productive behav-
iours during the previous week. All the items are rated
from 0 (‘never’) to 4 (‘almost always’). The score of all
scores is computed and the higher the global score, the
worse the work productivity [57].
Work Limitation Questionnaire (WLQ-25)
The WLQ-25 is a self-administered questionnaire used to
measure the impact of MDD on work performance. Is con-
sists of 25 items divided among four areas: time demands;
physical demands; mental/interpersonal demands; and out-
put demands. For each item, the participant has to rate the
amount of time he/she experienced difficulty (from ‘never’
to ‘always’) in the two most recent weeks [57].
Sheehan Disability Scale (SDS)
The SDS assesses functional impairment in the three fol-
lowing domains: work/school; social; and family life. It is a
brief self-report tool in which the participant has to rate
the extent to which he experienced disability and impair-
ment in those domains from 0 (not at all) to 10 (extremely)
during the past week. Additional questions estimate the
frequency of unproductivity at school/work [57].
Cognitive assessment (THINC-it tool)
The THINC-it tool has been developed to screen for
cognitive dysfunction in patients with MDD. The tasks
are consistently delivered in the following order: Spotter;
Symbol Check; Codebreaker; and Trails, with a clinician
blinded to treatment group instructing participants to
read the tutorial instructions preceding each of the
THINC-it tasks [58]. In addition, Perceived Deficits
Questionnaire-5-D (PDQ-5-D) is administered to all par-
ticipants. PDQ-5-D is a five-item auto-questionnaire
measuring subjectively reported cognitive deficits.
Spotter
The Spotter test is used to assess attention and speed of
response. In this test, participants are instructed to re-
spond by pressing keys on the left- or the right-hand
side of the keyboard corresponding to the direction to
which an arrow on the screen is pointing.
Symbol Check
The Symbol Check test measures working memory and
attention skills. In this test, the participant is presented a
series of stimuli at a constant rate. The task is to map
the currently presented stimulus on arrow keys of a key-
board to one they have recently seen in the stream (one
position back).
Codebreaker
The Codebreaker test, which is modelled on the digit
symbol substitution test (DSST), measures attention, per-
ceptual speed, motor speed, visual scanning and memory.
It requires the examinee to transcribe a unique geometric
symbol with its corresponding number. The examinee is
initially shown a key containing the numbers from 1 to 6.
Under each number, there is a corresponding geometric
symbol. The participant is then shown a series of numbers
on the screen and asked to match the number with the
corresponding geometric symbol.
Trails
The Trails test is designed to test elements of executive
function. Participants are instructed to connect a set of
18 dots as fast as possible while still maintaining accur-
acy. It can provide information about visual search
speed, scanning, speed of processing, mental flexibility,
as well as executive functioning.
Blood analysis
A blood test is taken during the screening visit for meas-
uring CRP levels, for the allocation into the ‘Depression
with inflammation’ and ‘Depression without inflammation’
strata of the study. Another blood test to measure haemo-
globin and a pregnancy test in premenopausal women is
performed at the same time. Anti-inflammatory medica-
tion is associated with higher risk of GI bleeding [59] and
haemoglobin levels have been suggested as a relevant
marker of GI damage [60]. Therefore, measuring haemo-
globin levels before treatment allows detection of potential
pre-existing GI damages. If haemoglobin levels are abnor-
mal, participants are referred to their treating doctor be-
fore starting the treatment. The pregnancy test is
performed since vortioxetine is classified as a category B3
drug in Australia, meaning that studies in animals have
shown evidence of an increased occurrence of fetal dam-
age, the significance of which is considered uncertain in
humans. Pregnant women therefore are not eligible for
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this trial. Blood tests are also performed at the baseline
visit, after six weeks of treatment and at the six-month
post-trial visit for analyses of serum inflammatory proteins
(TNF-α, IL-6 and IL-1β). The blood sample is collected
earlier (at last observation) if participants withdraw from
the study. The storage of biospecimens is split between
different secured freezers at the Adelaide Psychiatric Bio-
marker Centre at the Discipline of Psychiatry, University
of Adelaide, the Adelaide Health and Medical Sciences
building, all of which are monitored by a central alert sys-
tem 24 h/day seven days a week.
Results analysis
The primary outcome (change in MADRS score from
baseline to week 6) will be analysed using a mixed effects
model for repeated measurements (MMRM, all available
data), with freely varying mean and covariance structures.
Treatment will be included as fixed factors. The baseline
CRP level and stratified group (‘Depression with inflam-
mation’ versus ‘Depression without inflammation’) will be
controlled for. The existence of an interaction between in-
flammation at baseline and treatment will be assessed,
recognising that the study is only powered to detect very
large interaction effects. As previously recommended,
ANCOVA will be used to account for possible baseline
imbalance between treatment arms, thus allowing for par-
ticipant differences [61]. As previously stated, we hypothe-
sise that a reduction in MADRS score will be higher in
participants receiving vortioxetine plus celecoxib in the
‘Depression with inflammation’ stratum compared to par-
ticipants receiving the same treatment in the ‘Depression
with no inflammation’ stratum. The potential treatment
effect on CRP will be separated into the stratified strata
(‘Depression with inflammation’ versus ‘Depression with-
out inflammation’) as well as for the total group (all four
groups). For dichotomous endpoints, such as response
and remission, logistic regression with treatment as a fac-
tor and the baseline score as a covariate will be used. For
continuous endpoints, the same methodology as that de-
scribed for the primary endpoint will also be used. Con-
tinuous endpoints will also be analysed using observed
case (OC) and last observation carried forward (LOCF),
with LOCF being used to account for missing data and to
perform sensitivity analysis. Association between function
(FAST, Work Limitations Questionnaire and Sheehan Dis-
ability Scale) and endpoints addressing cognitive dysfunc-
tion will be explored by means of a partial correlation
coefficient. Adverse events and the CSSR-S will be sum-
marised using descriptive statistics.
Discussion
Abundant literature has highlighted that inflammation is
closely associated with depressive symptoms in patients
with MDD [6, 13, 24, 62–65]. Targeting inflammation
has therefore become a promising strategy in improving
depressive symptoms. Interestingly, numerous studies
demonstrate a beneficial effect of anti-inflammatory medi-
cations (e.g. NSAIDs or anti-cytokines) on depressive
symptoms in patients with MDD [34, 36, 38]. Specifically,
administering COX-2 inhibitors such as celecoxib in
addition to antidepressant treatment for six or eight weeks
improves treatment response and remission in compari-
son to antidepressant medication alone [48].
According to this literature, identifying individuals with
depression and inflammation could therefore help in devel-
oping new personalised treatment for MDD. However, to
our knowledge, there is no previous study assessing the
therapeutic effect of administering anti-inflammatory medi-
cation combined with antidepressant medication on the
basis of raised inflammatory markers at baseline. Through
the RCT we propose, we will be able to investigate the ef-
fectiveness of using a simple blood test, before treatment of
depression, to guide the use of anti-inflammatory medica-
tion as an addition to antidepressant medication in patients
with depression and inflammation. Indeed, if the efficacy of
augmenting vortioxetine with celecoxib 400 mg is higher in
participants with inflammation at baseline compared to
participants with no inflammation at baseline, it would be
recommended to use this augmentation strategy only in
MDD patients with raised inflammation before treatment.
The primary outcome of this study will be MADRS
score. It is expected that antidepressant combined with
anti-inflammatory medication will reduce MADRS score
by 50% from baseline to six weeks (end of treatment) in
the ‘Depression with inflammation’ stratum of the study.
We also expect that the reduction in MADRS score in
the ‘Depression with inflammation’ stratum will be larger
among those for whom vortioxetine treatment has been
augmented with celecoxib than those in the same
stratum receiving vortioxetine and placebo. Further-
more, the MADRS score reduction in the former group
will also surpass that achieved by both treatment groups
in the ‘Depression with no inflammation’ stratum. CRP
level as a secondary outcome measure is expected to be
reduced by 50% between baseline and six weeks in the
group treated with antidepressant and anti-inflammatory
medication in the ‘Depression with inflammation’
stratum of the study and is not expected to change in
the group treated with antidepressant only in the same
stratum. Similarly, CRP levels are not expected to be
changed following both treatments in the ‘Depression
with no inflammation’ stratum. Secondary outcome mea-
sures also include other inflammatory markers (TNF-α,
IL-6 and IL-1β), levels which are expected to be reduced
by 50%. In addition, a 50% improvement in cognitive
dysfunction, functional measures and workplace func-
tioning is expected. Finally, this study also assesses the
safety of the anti-inflammatory celecoxib 400 mg when
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combined with vortioxetine by measuring potential side
effects at each visit.
It is hypothesised that primary and secondary outcome
measures will not show a statistically significant differ-
ence between participants receiving vortioxetine only
and participants receiving vortioxetine plus celecoxib
within the ‘Depression with no inflammation’ stratum of
the study.
In summary, we anticipate that the results of this trial
will allow the development of a decision aid for depres-
sion medication, thus improving treatment response and
remission, especially in patients suffering from recurrent
treatment resistant depression.
Trial status
The trial has commenced recruitment and participant
inclusion in November 2017.
If any important changes to the study protocol become
necessary, where appropriate, the PI will notify the HREC,
trial register, financial sponsor, University and the present
journal. The HREC and PI, respectively, have the power to
end the study early if the need arises. The trial is subject
to audit at any time by the HREC and/or DMC.
Additional files
Additional file 1: Study information sheet. Detailed study information is
provided to participants during the screening visit before written consent
form is obtained. (PDF 368 kb)
Additional file 2: Participant consent form. The written informed
consent is obtained by the participants before starting the study. It states
that refusal to participate or subsequent withdrawal from the study will
in no way influence any treatment that the participant would receive, at
the time of the study or in the future. (DOCX 65 kb)
Additional file 3: SPIRIT checklist. SPIRIT checklist listing all the items
addressed in the current study protocol. (DOCX 49 kb)
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